In addition, GC treatment further increases Arg‐1 production in G‐MDSC, whereas iNOS and IDO levels remain unchanged, indicated that the MPPT could not enhance the expression of iNOS and IDO in MS patients. This evidence concerns the gene ARG1 and myeloid sarcoma.